Chester County News and Community Website
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced its participation in several upcoming investor conferences this September, highlighting opportunities to engage with the investment community.
Cabaletta Bio to Present at Multiple Investor Conferences in September Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) reported second-quarter financial results and provided a detailed business update, emphasizing progress toward a 2027 Biologics License Application (BLA) submission for its lead …
Cabaletta Bio Advances Rese-cel Pipeline as BLA Submission for Myositis Nears Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has unveiled new clinical and translational data from its ongoing RESET-Myositis™, RESET-SLE™, and RESET-SSc™ trials. The findings highlight potential breakthroughs for rese-cel …
Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced the pricing of its underwritten public offering, aiming to raise approximately $100 million in gross proceeds. The offering comprises 39,200,000 …
Cabaletta Bio Prices Public Offering to Raise $100 Million Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced today it has started an underwritten public offering of common stock and accompanying warrants (or pre-funded warrants in lieu of common …
Cabaletta Bio Announces Public Offering of Common Stock and Warrants Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 11:05 a.m. ET in …
Cabaletta Bio to Present at Jefferies Global Healthcare Conference 2025 Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced key updates on its RESET-Myositis trial and plans for the anticipated 2027 Biologics License Application (BLA) submission for rese-cel (resecabtagene …
Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its financial results for the fourth quarter and full year 2024, along with significant updates across its clinical programs. The company, …
Cabaletta Bio Reports Strong Clinical Progress and Q4 2024 Financial Results Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its participation in the TD Cowen 45th Annual Health Care Conference, scheduled to take place on Monday, March 3, 2025, …
Cabaletta Bio to Present at TD Cowen 45th Annual Health Care Conference Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) shared new and updated results from its RESET clinical development program at major scientific conferences, presenting data on the first 10 patients treated …
Cabaletta Bio Reveals Promising Clinical Data for Autoimmune Therapy Read More